|Mr. Roger Hofseth||Chief Exec. Officer||N/A||N/A||1974|
|Mr. Jon Olav Ødegård||Chief Financial Officer||1.7M||N/A||N/A|
|Mr. Karl Inge Slotsvik||Chief Operating Officer||1.2M||N/A||N/A|
|Dr. Bomi Framroze||Chief Scientific Officer||21.73M||N/A||1961|
|Ms. Henriette Godø Heggdal||Lab Mang. & Director||896k||N/A||1981|
|Mr. James Berger||Chief Commercial Officer||7.81M||N/A||N/A|
|Angelika Florvaag||Chief Quality Officer||822k||N/A||N/A|
|Mr. Kai Morten Thuen||Head of Commercial Excellence||N/A||N/A||1977|
|Dr. Crawford Currie||Head of Medical R&D||N/A||N/A||N/A|
|Dr. Tanja Schaffer||EVP of Global Ingredients Division & CEO of HBC Switzerland GmbH||N/A||N/A||N/A|
Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.
Hofseth BioCare ASA’s ISS governance QualityScore as of 1 July 2022 is 5. The pillar scores are Audit: 10; Board: 3; Shareholder rights: 1; Compensation: 8.